Circulating tumor cells therapeutic apheresis: a novel biotechnology enabling personalized therapy for all cancer patients

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Circulating tumor cells therapeutic apheresis: a novel biotechnology enabling personalized therapy for all cancer patients
Project Number: CORDIS-105310
Project web address: Follow on CORDIS
Organization: Universiteit Twente, Netherlands, Enschede
Collaborators: Heinrich-Heine-Universitat At Dusseldorf, DE
Eberhard Karl University Of Tuebingen, DE
Institut Gustave Roussy, FR
Institute Of Cancer Research : Royal Cancer Hospital, GB
Aquamarijn Micro Filtration B.V., NL
Magyar Tudomanyos Akademia Szegedibiologiai Kutatokozpont, HU
Asper Biotech As, EE
Participant Legal Name Istituto Oncologico Veneto Irccs, IT
Leukocare Ag, DE
Aczon Srl, IT
Principal Investigators (PI): Ferdinand Damhuis, NL
Arnauld Forest, FR
Anu Aaspõllu, EE
Lydia Turner, GB
Doris Neubert, DE
Martin Scholz, DE
Rita Zamarchi, IT
Brigitte Rack, DE
Alfredo Ventola, IT
Arjan Tibbe, NL
Tanja Fehm, DE
Csaba Vizler, HU
 
Project Description:
Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treatment regiment. However a biopsy can frequently not be obtained without risk and or discomfort to the patient. Circulating tumor cells (CTC) may circumvent this problem.CTC refer to cells that detach from a primary tumor or metastatic site, circulate in the peripheral blood and may form metastasis. CTC represent a ""liquid biopsy"" that can be used to tailor treatment for individual patients. CTC are however rare and can only be obtained for further characterization in a small fraction of patients.In the CTCtrap consortium universities, research institutions and SMEs are linked in a common effort, starting from the simple, but innovative view of using Therapeutic Apheresis (TA), as a way to collect CTC from peripheral blood in cancer patients.A new TA column will be developed to capture CTC and then reintroduce the blood devoid of tumor cells back into the body with the promise to obtain CTC in all patients at risk for recurrence or diagnosed with metastatic disease. The molecular characterization of these CTC is expected to gather new knowledge on metastasis' mechanism, provide a risk assessment and the optimal therapy choice during the course of the disease of cancer patients. The new knowledge on CTC heterogeneity within cancer type and within individuals will allow for the tuning of CTCapheresis to specific cancer types. Prospective pilot studies will be setup to investigate the feasibility of the CTCapheresis in the clinic and their potential therapeutic benefit.Success of CTCapheresis will lead to a radical change in the diagnosis and treatment of solid tumors.
 
Project Terms:
scientific research
Project Title: Circulating tumor cells therapeutic apheresis: a novel biotechnology enabling personalized therapy for all cancer patients
Project Number: CORDIS-105310
Project web address: Follow on CORDIS
Organization: Universiteit Twente, Netherlands, Enschede
Collaborators: Heinrich-Heine-Universitat At Dusseldorf, DE
Eberhard Karl University Of Tuebingen, DE
Institut Gustave Roussy, FR
Institute Of Cancer Research : Royal Cancer Hospital, GB
Aquamarijn Micro Filtration B.V., NL
Magyar Tudomanyos Akademia Szegedibiologiai Kutatokozpont, HU
Asper Biotech As, EE
Participant Legal Name Istituto Oncologico Veneto Irccs, IT
Leukocare Ag, DE
Aczon Srl, IT
Principal Investigators (PI): Ferdinand Damhuis, NL
Arnauld Forest, FR
Anu Aaspõllu, EE
Lydia Turner, GB
Doris Neubert, DE
Martin Scholz, DE
Rita Zamarchi, IT
Brigitte Rack, DE
Alfredo Ventola, IT
Arjan Tibbe, NL
Tanja Fehm, DE
Csaba Vizler, HU
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology > Cancer & related diseases > Malignant neoplasms (including in situ)
 
Other Information:
Fiscal Year: 2012
Project Start Date: 1 September 2012
Project End Date: 31 August 2016
Project program: FP7-HEALTH
 
Project Funding Information:
Funding Mechanism: CP-FP - Small or medium-scale focused research project
Year Funding Organization Total Funding, $
2012 European Research Council $9,154,128